Lloyd, R.D.; Osamura, R.V.; Klöppel, G. WHO Classifiation of Tumors of Endocrine Organs, 4th ed; , 2017, Vol. 10, .
Jaume, Capdevil; Ignacio Matos, Garcia Francesco M Mancuso, Carmela Iglesias, Paolo Nuciforo, Carles Zafon, Hector G. Palmer, Zighereda Ogbah, Laura Muiños, Carol Elaine Pena, Marcia S. Brose, Martin Schlumberger, Ana Vivancos. RNAseq analysis of the sorafenib phase III DECISION trial in differentiated thyroid cancer (DTC): Correlation with clinical outcome. J. Clin. Oncol., 2017, 35(15_suppl), 6083-6083.
Matos, I; Mancuso, F; Iglesias, C. Prognostic impact of RNA expression profile (EP) in the phase III DECISION trial for patients with advanced radioactive-iodine refractory differentiated thyroid cancer (DTC). Ann Oncol, 2017, 28(Issue suppl_5)
Bowles, DW; Ross, JS; Gay, LM Comprehensive genomic profiling of anaplastic thyroid carcinoma. J Clin Oncol, 2018, 36(suppl;abstr 6089)
Schlumberger, M; Newbold, K; Hasan, B A randomized doubled blind phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients (pts) with differentiated thyroid carcinoma (CTD) progressing after first line therapy: EORTC 1209. J Clin Oncol., 2018, 36(suppl; abstr 6021)
Brose, MS; Shenoy, S; Bhat, N A phase II trial of cabozantinib (CABO) for the treatment of radioiodine (RAI)-refractory differentiated thyroid carcinoma (DTC) in the first-line setting. J Clin Oncol., 2018, 36(suppl; abstr 6088)
Ito, Y.; Onoda, N. Ito, KI Sorafenib in Japanese patients with locally advanced or metastatic medullary thyroid carcinoma and anaplastic thyroid carcinoma. Thyroid, 2017, 27(9), 1142-1148.
Manisha, S.H.; Wei, L.; Wirth, L.J. Results of randomized phase 2 trial of dabrafenib versus dabrefenib plus trametinib in BRAF-mutated papillary thyroid carcinoma. J. Clin. Oncol., 2017, 35(15 suppl), 6022-6022.
Sherman, EJ; Ho, AL Fagin JA Combination of dabrafenib (DAB) and lapatinib (LAP) for the treatment of BRAFmutant thyroid cancer. J Clin Oncol, 2018, 36(suppl;abstr 6087)
Rothenberg, SM; McFadden, DG Palmer, EL Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib. Clin Cancer Res., 2015. 1March; 21 (5), 1028-1035
Subbiah, V.; Taylor, M.; Lin, J. Highly potent and selective RET inhibitor, BLU-667, achieves proof of concept in a phase I study of advanced, RET-altered solid tumors. AACR Annual Meeting. Abstract CT043., 2018. Presented April 15, 2018.
Drilon, AE; Subbiah, V; Oxnard, GR A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers. J Clin Oncol., 2018, 36(suppl; abstr 102)
Sherman, EJ; Ho, AL; Fury, SS Combination of everolimus and sorafenib in the treatment of thyroid cancer. Update of the phase II study. J Clin Oncol, 2015, 33(suppl; abstr 6069)
Rottenburger, C; Nicolas, G; McDougall, L Title evaluation of the CCK-2-receptor agonist 177Lu-PP-F1N for peptide receptor radionuclide therapy (PRRT) of medullary thyroid carcinoma – First results of a phase 0 ‘Lumed’ Study. Endoc Abstr, 2018, 56(GP234)
Mehnert, JM; Varga, A Marcia Brose, M Pembrolizumab for advanced papillary or follicular thyroid cancer: preliminary results from the phase 1b KEYNOTE-028 study. J Clin Oncol, 2016, 34(suppl; abstr 6091)
Wirth, LJ; Eigendorff, E; Capdevila, J Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with anaplastic thyroid cancer. J Clin Oncol., 2018, 36(suppl; abstr 6024)